Novo Nordisk—manufacturer of diabetes and weight-loss drugs Ozempic and Wegovy—filed lawsuits against two pharmacies after ... filed lawsuits against the Florida-based Wells Pharmacy Network ...

Novo Nordisk said Friday it settled two lawsuits against two businesses claiming to offer compounded versions of its blockbuster drugs Ozempic and Wegovy. The drugmaker has filed a total of 12 ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Korro will advance up to two programs through preclinical development after which point Novo Nordisk could further advance the programs through clinical studies. Korro Bio NewsMORE Related Stocks ...

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week. Wegovy has been FDA-approved ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Korro will advance up to two programs through preclinical development after which point Novo Nordisk could further advance the programs through clinical studies. About Korro Korro is a ...

The collaboration brings together Novo Nordisk’s deep cardiometabolic disease understanding and drug development experience with Korro’s proprietary platform to develop ...